Results 1 to 10 of about 20,432 (139)

Efavirenz: History, Development and Future

Biomolecules, 2022
Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the spread of HIV.
Bárbara Costa, Nuno Vale
doaj   +1 more source

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. [PDF]

PLoS ONE, 2013
We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations.ART naïve HIV patients from Ethiopia (n = 285) and Tanzania (n = 209 ...
Eliford Ngaimisi, Abiy Habtewold, Omary Minzi, Eyasu Makonnen, Sabina Mugusi, Wondwossen Amogne, Getnet Yimer, Klaus-Dieter Riedel, Mohammed Janabi, Getachew Aderaye, Ferdinand Mugusi, Leif Bertilsson, Eleni Aklillu, Juergen Burhenne   +13 more
doaj   +1 more source

Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz

Biomedicines, 2022
Drug-induced liver injury (DILI) constitutes a clinical challenge due to the incomplete characterization of the mechanisms involved and potential risk factors.
Fernando Alegre, Alberto Martí-Rodrigo, Miriam Polo, Dolores Ortiz-Masiá, Celia Bañuls, Marcello Pinti, Ángeles Álvarez, Nadezda Apostolova, Juan V. Esplugues, Ana Blas-García   +9 more
doaj   +1 more source

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations

Frontiers in Pharmacology, 2020
Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we investigated the impact of population and pharmacogenetic variations for ...
Sabina Mugusi, Sabina Mugusi, Abiy Habtewold, Eliford Ngaimisi, Wondwossen Amogne, Getnet Yimer, Omary Minzi, Eyasu Makonnen, Eyasu Makonnen, Christopher Sudfeld, Jürgen Burhenne, Eleni Aklillu   +11 more
doaj   +1 more source

Therapeutic activities of naringenin on efavirenz-induced sleep-like disorder in the midbrain of white albino mice [PDF]

Iranian Journal of Basic Medical Sciences, 2020
Objective(s): Efavirenz, has proven to be effective in suppressing human immunodeficiency virus (HIV) viral load; however, complaints of sleep disorders including hallucination, and insomnia have greatly contributed to non-adherence to antiretroviral ...
Olufunke Dosumu, Edidiong Akang, Oluwatomisin Faniyan, Alani Akanmu   +3 more
doaj   +1 more source

Neuropsychiatric and Neurocognitive Manifestations in HIV-Infected Children Treated With Efavirenz in South Africa—A Retrospective Case Series

Frontiers in Neurology, 2019
Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on neurocognition in children is unknown. Genetically slow metabolizers of efavirenz may be at risk of toxicity.
Charles K. Hammond, Charles K. Hammond, Brian Eley, Natalia Ing, Jo M. Wilmshurst   +4 more
doaj   +1 more source

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).

PLoS ONE, 2014
ObjectiveTo assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.MethodsHIV-infected adults with CD4+ T cell count ≤ 200/mm(3) received ...
Laurence Borand, Yoann Madec, Didier Laureillard, Monidarin Chou, Olivier Marcy, Phearavin Pheng, Narom Prak, Chindamony Kim, Khemarin Kim Lak, Chanroeun Hak, Bunnet Dim, Eric Nerrienet, Arnaud Fontanet, Thim Sok, Anne E Goldfeld, François-Xavier Blanc, Anne-Marie Taburet   +16 more
doaj   +1 more source

Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa

Southern African Journal of HIV Medicine, 2023
Background: The neuropsychiatric side effects of efavirenz occur mainly early during treatment and are usually mild. A lesser-known and serious complication is late-onset efavirenz toxicity causing ataxia and encephalopathy. Data regarding this condition
Lyneshree Munsami, Clara M. Schutte, Maryke de Villiers, Juliane Hiesgen   +3 more
doaj   +1 more source

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania

BMC Pharmacology and Toxicology, 2018
Background Children are subject to varying drug pharmacokinetics which influence plasma drug levels, and hence treatment outcomes especially for drugs like efavirenz whose plasma concentrations are directly related to treatment outcomes.
Selemani Saidi Sungi, Eliford Ngaimisi, Nzovu Ulenga, Philip Sasi, Sabina Mugusi   +4 more
doaj   +1 more source

Efavirenz exposure, alone and in combination with known drugs of abuse, engenders addictive-like bio-behavioural changes in rats

Scientific Reports, 2018
Efavirenz is abused in a cannabis-containing mixture known as Nyaope. The addictive-like effects of efavirenz (5, 10 and 20 mg/kg) was explored using conditioned place preference (CPP) in rats following sub-acute exposure vs. methamphetamine (MA; 1 mg/kg)
Marisa Möller, Jaco Fourie, Brian H. Harvey   +2 more
doaj   +1 more source